If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Dr. Fehniger is interested in understanding innate immunity and its relationship to cancer. He focuses on the molecular and cellular biology of one innate immune lymphocyte, the natural killer cell, and developing translational immunotherapy strategies that utilize natural killer cells to fight cancer.

Areas of Clinical Interest

Lymphoma, cellular therapy and bone marrow transplantation

Fingerprint Dive into the research topics where Todd Fehniger is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 26 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma

Shea, L., Watkins, M. P., Wan, F., Cashen, A., Wagner-Johnston, N. D., Jacoby, M. A., Abboud, C. N., Dipersio, J. F., Hurd, D. D., Jaglowski, S. M., Bartlett, N. L. & Fehniger, T. A., 2020, (Accepted/In press) In : Biology of Blood and Marrow Transplantation.

Research output: Contribution to journalArticle

  • Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis

    Mack, M. R., Brestoff, J. R., Berrien-Elliott, M. M., Trier, A. M., Yang, T. L. B., McCullen, M., Collins, P. L., Niu, H., Bodet, N. D., Wagner, J. A., Park, E., Xu, A. Z., Wang, F., Chibnall, R., Council, M. L., Heffington, C., Kreisel, F., Margolis, D. J., Sheinbein, D., Lovato, P. & 7 others, Vivier, E., Cella, M., Colonna, M., Yokoyama, W. M., Oltz, G., Fehniger, T. A. & Kim, B. S., Feb 26 2020, In : Science translational medicine. 12, 532, aay1005.

    Research output: Contribution to journalArticle

  • 7 Scopus citations

    CD56 regulates human NK cell cytotoxicity through Pyk2

    Gunesch, J. T., Dixon, A. L., Ebrahim, T. A. M., Berrien-Elliott, M. M., Tatineni, S., Kumar, T., Hegewisch-Solloa, E., Fehniger, T. A. & Mace, E. M., Jun 2020, In : eLife. 9, p. 1-28 28 p., e57346.

    Research output: Contribution to journalArticle

    Open Access
  • Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient

    Oza, A., Rettig, M. P., Powell, P., O'Brien, K., Clifford, D. B., Ritchey, J., Gehrs, L., Hollaway, J., Major, E., Fehniger, T. A., Miller, C. A., Soon-Shiong, P., Rock, A. & DiPersio, J. F., Jun 9 2020, In : Blood Advances. 4, 11, p. 2387-2391 5 p.

    Research output: Contribution to journalArticle

    Open Access
    1 Scopus citations

    KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation

    Weisdorf, D., Cooley, S., Wang, T., Trachtenberg, E., Vierra-Green, C., Spellman, S., A. Sees, J., Spahn, A., Vogel, J., Fehniger, T. A., Woolfrey, A. E., Devine, S. M., Ross, M., Waller, E. K., Sobecks, R. M., McGuirk, J., Oran, B., Farag, S. S., Shore, T., Van Besien, K. & 4 others, Marsh, S. G. E., Guethlein, L. A., Parham, P. & Miller, J. S., Feb 25 2020, In : Blood Advances. 4, 4, p. 740-754 15 p.

    Research output: Contribution to journalArticle

    Open Access
  • 4 Scopus citations